IRRAS Announces Changed Publication Date for the Q1 2022 Interim Report

Stockholm, Sweden (April 25, 2022) IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that the publication of the company’s interim report for the period from January to March 2022 (“Q1 2022 Interim Report”) will be published on Wednesday, 27 April 2022.

Financial calendar for 2022

Report Previously Announced Date New Date
Q1 2022 interim report 10 May 2022 27 April 2022
Q2 2022 interim report 22 July 2022 Unchanged
Q3 2022 interim report 10 November 2022 Unchanged


IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:
Sten Gustafsson
Director, Investor Relations
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on April 25, 2022, at 8:30 (CET).

Irras Radio Irras Academy

At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data.
By using the website, you acknowledge and accept our policy.